Mazdutide vs Survodutide: prices, identity and regulatory status (2026)
Mazdutide and Survodutide are different research compounds, not substitutes for each other: Mazdutide is a single compound (C207H317N45O65); Survodutide is a single compound (C192H289N47O61). Neither product has a current in-stock price right now. Mazdutide has no Drugs@FDA application; Survodutide has no Drugs@FDA application.
Mazdutide vs Survodutide: current prices and packages
| Compared property | Mazdutide | Survodutide |
|---|---|---|
| Category | GLP-1 | GLP-1 |
| Compared package | 10mg · Vial | 10mg · Vial |
| Lowest current price | No current in-stock price | No current in-stock price |
| Price per labelled mg | — | — |
| Package sizes | 5mg, 10mg | 5mg, 6mg, 10mg |
| Vendors with current prices | 0 (1 tracked) | 0 (1 tracked) |
| Form at this package | Vial | Vial |
| Stock | Out of stock | Out of stock |
Prices exclude shipping. The price per labelled mg is always given per mg, so different package sizes compare directly; it is shown only for single-compound vials and powders with a labelled mass. Blends, capsules, liquids and IU-labelled packages are compared by package total.
Identity, regulatory status and registered research
| Compared property | Mazdutide | Survodutide |
|---|---|---|
| Molecular formula | C207H317N45O65 | C192H289N47O61 |
| Molecular weight | 4476 g/mol | 4232 g/mol |
| Sequence | — | — |
| CAS Registry Number | — | — |
| Registered clinical trials | 40 (24 active) · Phase 4: 5, Phase 3: 11, Phase 2: 12 | 27 (9 active) · Phase 3: 11, Phase 2: 3, Phase 1: 13 |
| Human intervention studies | 6 | 6 |
| US regulatory status | No Drugs@FDA application (checked October 7, 2026) · Drugs@FDA search | No Drugs@FDA application (checked October 7, 2026) · Drugs@FDA search |
Identity data: PubChem, FDA GSRS and EPA records; registry counts: ClinicalTrials.gov; status: Drugs@FDA. A matching name does not verify the contents of a supplier's lot.
Key human studies
Mazdutide
- Mazdutide versus dulaglutide in Chinese adults with type 2 diabetes. Nature, 2026
- Mazdutide versus placebo in Chinese adults with type 2 diabetes. Nature, 2026
- Treatment With 9-mg Mazdutide for Weight Reduction in Chinese Adults With Obesity: The GLORY-2 Randomized Clinical Trial. JAMA, 2026
Survodutide
- Survodutide Once Weekly for the Treatment of Adults with Obesity. The New England journal of medicine, 2026
- Survodutide in adults with obesity and metabolic dysfunction-associated steatotic liver disease: SYNCHRONIZE-MASLD, a randomized, double-blind, placebo-controlled phase 3 trial. Nature medicine, 2026
- A Phase 2 Randomized Trial of Survodutide in MASH and Fibrosis. The New England journal of medicine, 2024
Studies are listed as records, newest first; they are not evidence that a research product is safe or effective.
Where to buy each compound
Mazdutide
Mazdutide is a catalogue entry whose compound-specific reference review has not yet been completed.
No vendor has a current in-stock price for this package.
Mazdutide prices →Price history →Survodutide
Survodutide is a catalogue entry whose compound-specific reference review has not yet been completed.
No vendor has a current in-stock price for this package.
Survodutide prices →Price history →Related comparisons
Questions
Automated price sources are scheduled daily; other sources are checked manually. Check the offer's last successful source timestamp. A code is shown when it is attached to an offer or affiliate link. The displayed price includes a discount only when that code is cart-verified and the discounted price is explicitly recorded; otherwise it is the vendor's listed price. Prices exclude shipping. Stock status is captured at the same time. Rankings are by displayed price, except that the labelled featured partner, LA Peptides, is pinned first; “Cheapest” always marks the lowest price. PeptideTech earns a commission when you buy through a link.
Full method →